Trial Design

A representative sample patient population that accurately reflects the overall population is vital to establish the safety and efficacy of a drug.

Harnessing these tools for successful integration and streamlining of processes.

Webinar Date/Time: Wednesday, May 22, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

The current clinical development model is shifting toward a generative AI-augmented proactive approach supported by real-world data for real time evidence.

Following a webinar on the use of a medical device in a migraine clinical trial, Mowlem caught up with ACT to discuss her biggest takeaways and what she is currently seeing in the digital trials space.

Webinar Date/Time: Tuesday, May 7th, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

Amplifying the size and diversity of participant pools in clinical trials enhances statistical power and increases the generalizability of study findings.

New and renewed approaches to improve chances of success in developing non-addictive drugs for chronic pain.

In light of scant published data from sponsors and contract research organizations on site activation and recruitment challenges following the COVID-19 pandemic, the primary objective of this research is to revisit the results of recruitment and retention tactics in studies conducted in 2012 and 2019.

Transparent and detailed communication throughout the research process is key for effectively recruiting and retaining patients for clinical trials.

The clinical research industry is increasingly leveraging insights, experience, and advanced solutions to better implement diversity and inclusion initiatives.

Tola Olorunnisola, senior vice president – general manager, clinical services and strategy, at Avantor, discusses the progress and challenges in incorporating more diversity-driven measures in drug development.

Spotlight on poor compliance, access, and usefulness of trial results summaries.

Despite industry-wide excitement over the involvement of retail pharmacies in clinical research, there is little information currently available on how retail pharmacies are perceived by investigative sites and patients.

Webinar Date/Time: Thu, Mar 28, 2024 12:00 PM EDT

While little research on open-cohort designs currently exists, could this design be a solution to challenges currently seen in closed-cohort designs?

A framework to understand the different approaches of trial matching solutions and the major operational and workflow challenges that all matching solutions share.

The FDA has taken a clear position with Project Optimus in shifting toward more progressive tailored approaches while rejecting antiquated study designs to evolve clinical trial strategies to better align with newer drug classes.

Webinar Date/Time: Tue, Mar 26, 2024 11:00 AM EDT

It is crucial throughout the clinical trials space to understand the challenges and triumphs of DEI.

Webinar Date/Time: Tuesday, March 12th, 2024 at 12pm EDT | 9am PDT | 4pm GMT | 5pm CET

The DCT-driven evolution requires new levels of understanding and expertise.

Despite repeated calls from the FDA, patient advocates, and scholars for the need to address demographic disparities in clinical research, White participants still remain overrepresented while racial minority participants remain underrepresented in clinical trials.

Webinar Date/Time: Wed, Mar 27, 2024 11:00 AM EDT

For effective rollout on a global scale, sponsors must address and develop a plan around known challenges including recruitment, sit adoption, and technology integration.

Webinar Date/Time: Wednesday, February 14th, 2024 at 11am EST | 8am PST | 4pm GMT | 5pm CET

Expanding clinical trial access to include historically underrepresented ethnic and racial minorities means addressing root-cause barriers, including taxation.

DCTs, data, and analytics are all areas that could be impacted in the near future.

Parents of children with cancer and limited health literacy were associated with lower comprehension of informed consent.